Skip to main content
. Author manuscript; available in PMC: 2016 Apr 25.
Published in final edited form as: Vaccine. 2014 May 14;32(30):3780–3786. doi: 10.1016/j.vaccine.2014.05.014

Figure 4.

Figure 4

Reduction in the annual number of cCMV infections, by type of maternal infection, at equilibrium by duration of vaccine protection, assuming age-specific duration of infectiousness, 20 year duration of latency, 90% vaccine coverage, 70% vaccine efficacy, and vaccination at 12-18 months or 15-19 years of age, United States and Brazil.

In figure 4c, black lines indicate impact of vaccination at 12-18 months of age only and gray lines indicate impact of combined schedule with vaccination at 12-18 months of age and 15-19 years of age.